Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...
The field of transfusion medicine has long sought effective alternatives to human blood, focusing increasingly on bio-synthetic blood substitutes and ...
Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section on Artivabio.com. A webcast replay will be made available following the ...
Hosted on MSN1d
Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should KnowThe market expects Iovance Biotherapeutics (IOVA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known ...
The market's underestimating how well each of these companies should be able to capitalize on their opportunities.
allAfrica.com on MSN4d
Uganda Treats First Patient Using Stem Cell TherapyUganda has treated its first patient using advanced stem cell therapy, marking a ground-breaking milestone in East Africa's medical history.Stem cell therapy, also known as regenerative medicine, uses ...
A Philadelphia biotechnology company founded seven years ago by two former Johnson & Johnson executives has a new leader.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback